Click here to get full coverage on URGN SEC Filings - Urogen Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

URGN SEC Filings - Urogen Pharma 10-K, 10-Q, 8-K Forms  Stock Titan

URGN SEC Filings - Urogen Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

Click here to get full coverage on How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities - Yahoo Finance

How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities  Yahoo Finance

How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities - Yahoo Finance

Click here to get full coverage on URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe - GuruFocus

URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe  GuruFocus

URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe - GuruFocus

Click here to get full coverage on URGN PE Ratio & Valuation, Is URGN Overvalued - intellectia.ai

URGN PE Ratio & Valuation, Is URGN Overvalued  intellectia.ai

URGN PE Ratio & Valuation, Is URGN Overvalued - intellectia.ai

Click here to get full coverage on UroGen Pharma Ltd. - Ordinary Shares (NQ: URGN - The Chronicle-Journal

UroGen Pharma Ltd. - Ordinary Shares (NQ: URGN  The Chronicle-Journal

UroGen Pharma Ltd. - Ordinary Shares (NQ: URGN - The Chronicle-Journal

Click here to get full coverage on SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN - MarketBeat

SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN  MarketBeat

SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN - MarketBeat

Click here to get full coverage on $URGN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$URGN stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$URGN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on UroGen Pharma Ltd. Ordinary Shares (URGN) Stock Price Today & Analysis - heygotrade.com

UroGen Pharma Ltd. Ordinary Shares (URGN) Stock Price Today & Analysis  heygotrade.com

UroGen Pharma Ltd. Ordinary Shares (URGN) Stock Price Today & Analysis - heygotrade.com

Click here to get full coverage on UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha

UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates  Seeking Alpha

UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha

Click here to get full coverage on Bladder cancer drug kept 72.2% of responders event-free for 2 years - Stock Titan

Bladder cancer drug kept 72.2% of responders event-free for 2 years  Stock Titan

Bladder cancer drug kept 72.2% of responders event-free for 2 years - Stock Titan

Click here to get full coverage on Market Sentiment Around Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st

Market Sentiment Around Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN)  simplywall.st

Market Sentiment Around Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st

Click here to get full coverage on UroGen Pharma (URGN) Announces Positive Phase 3 Trial Results fo - GuruFocus

UroGen Pharma (URGN) Announces Positive Phase 3 Trial Results fo  GuruFocus

UroGen Pharma (URGN) Announces Positive Phase 3 Trial Results fo - GuruFocus

Click here to get full coverage on Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance

Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term  Yahoo Finance

Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts  MarketBeat

Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Click here to get full coverage on Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report - Yahoo Finance

Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report  Yahoo Finance

Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report - Yahoo Finance

Click here to get full coverage on Bladder cancer survey: 80% of patients live with fear it will return - Stock Titan

Bladder cancer survey: 80% of patients live with fear it will return  Stock Titan

Bladder cancer survey: 80% of patients live with fear it will return - Stock Titan

Click here to get full coverage on Why UroGen Pharma (URGN) Is Up 15.0% After FDA Backs UGN-103 and Reports Strong Trial Results - Yahoo Finance

Why UroGen Pharma (URGN) Is Up 15.0% After FDA Backs UGN-103 and Reports Strong Trial Results  Yahoo Finance

Why UroGen Pharma (URGN) Is Up 15.0% After FDA Backs UGN-103 and Reports Strong Trial Results - Yahoo Finance

Click here to get full coverage on Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates  Yahoo Finance

Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance

Click here to get full coverage on UroGen grants 51,200 stock units to new hires backing cancer drugs - Stock Titan

UroGen grants 51,200 stock units to new hires backing cancer drugs  Stock Titan

UroGen grants 51,200 stock units to new hires backing cancer drugs - Stock Titan

Click here to get full coverage on UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates  Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

Click here to get full coverage on UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st

UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected  simplywall.st

UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st

Click here to get full coverage on Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri - TradingView

Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri  TradingView

Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri - TradingView

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance

Click here to get full coverage on JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN - MarketBeat

JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN  MarketBeat

JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN - MarketBeat

Click here to get full coverage on $URGN stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

$URGN stock is up 16% today. Here's what we see in our data.  Quiver Quantitative

$URGN stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman - PR Newswire

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman  PR Newswire

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman - PR Newswire

Click here to get full coverage on Insider Sale: General Counsel of $URGN Sells 1,608 Shares | URGN Stock News - Quiver Quantitative

Insider Sale: General Counsel of $URGN Sells 1,608 Shares | URGN Stock News  Quiver Quantitative

Insider Sale: General Counsel of $URGN Sells 1,608 Shares | URGN Stock News - Quiver Quantitative

Click here to get full coverage on How (URGN) Movements Inform Risk Allocation Models - Stock Traders Daily

How (URGN) Movements Inform Risk Allocation Models  Stock Traders Daily

How (URGN) Movements Inform Risk Allocation Models - Stock Traders Daily

Click here to get full coverage on UroGen: Expect Rough Patch Before Strong Recovery In 2026 (NASDAQ:URGN) - Seeking Alpha

UroGen: Expect Rough Patch Before Strong Recovery In 2026 (NASDAQ:URGN)  Seeking Alpha

UroGen: Expect Rough Patch Before Strong Recovery In 2026 (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN) - Seeking Alpha

UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN)  Seeking Alpha

UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on UroGen Pharma (URGN) director converts 2,000 RSUs into 2,000 ordinary shares - Stock Titan

UroGen Pharma (URGN) director converts 2,000 RSUs into 2,000 ordinary shares  Stock Titan

UroGen Pharma (URGN) director converts 2,000 RSUs into 2,000 ordinary shares - Stock Titan

Click here to get full coverage on UroGen Pharma Ltd. to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative

UroGen Pharma Ltd. to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026  Quiver Quantitative

UroGen Pharma Ltd. to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative

Click here to get full coverage on Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors - simplywall.st

Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors  simplywall.st

Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors - simplywall.st

Click here to get full coverage on Biotech UroGen Pharma sets March 2 call on 2025 results - Stock Titan

Biotech UroGen Pharma sets March 2 call on 2025 results  Stock Titan

Biotech UroGen Pharma sets March 2 call on 2025 results - Stock Titan

Click here to get full coverage on UroGen Pharma (URGN) Highlights Key Findings in Bladder Cancer R - GuruFocus

UroGen Pharma (URGN) Highlights Key Findings in Bladder Cancer R  GuruFocus

UroGen Pharma (URGN) Highlights Key Findings in Bladder Cancer R - GuruFocus

Click here to get full coverage on Bladder cancer trial: ZUSDURI keeps many patients recurrence-free for 2 years - Stock Titan

Bladder cancer trial: ZUSDURI keeps many patients recurrence-free for 2 years  Stock Titan

Bladder cancer trial: ZUSDURI keeps many patients recurrence-free for 2 years - Stock Titan

Click here to get full coverage on UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha

UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers  Seeking Alpha

UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha

Click here to get full coverage on With UroGen Pharma Stock Sliding, Have You Assessed The Risk? - Trefis

With UroGen Pharma Stock Sliding, Have You Assessed The Risk?  Trefis

With UroGen Pharma Stock Sliding, Have You Assessed The Risk? - Trefis

Click here to get full coverage on (URGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily

(URGN) and the Role of Price-Sensitive Allocations  Stock Traders Daily

(URGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Click here to get full coverage on UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN) - simplywall.st

UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN)  simplywall.st

UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN) - simplywall.st

Click here to get full coverage on Guggenheim Sticks to Their Buy Rating for Urogen Pharma (URGN) - The Globe and Mail

Guggenheim Sticks to Their Buy Rating for Urogen Pharma (URGN)  The Globe and Mail

Guggenheim Sticks to Their Buy Rating for Urogen Pharma (URGN) - The Globe and Mail

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat - MarketBeat

Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat  MarketBeat

Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat - MarketBeat

Click here to get full coverage on Understanding the Setup: (URGN) and Scalable Risk - Stock Traders Daily

Understanding the Setup: (URGN) and Scalable Risk  Stock Traders Daily

Understanding the Setup: (URGN) and Scalable Risk - Stock Traders Daily

Click here to get full coverage on Paradigm Entities Hold 5.0% of UroGen Ordinary Shares - Stock Titan

Paradigm Entities Hold 5.0% of UroGen Ordinary Shares  Stock Titan

Paradigm Entities Hold 5.0% of UroGen Ordinary Shares - Stock Titan

Click here to get full coverage on UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN)  Seeking Alpha

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

Click here to get full coverage on URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN) - Business Wire

URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN)  Business Wire

URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN) - Business Wire

Click here to get full coverage on UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors - GlobeNewswire

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors  GlobeNewswire

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors - GlobeNewswire

Click here to get full coverage on UroGen Pharma Earnings Preview - benzinga.com

UroGen Pharma Earnings Preview  benzinga.com

UroGen Pharma Earnings Preview - benzinga.com

Click here to get full coverage on Earnings Flash (URGN) UroGen Pharma Posts Q4 Net Loss $0.54 a Share, vs. FactSet Est of $0.50 Loss - marketscreener.com

Earnings Flash (URGN) UroGen Pharma Posts Q4 Net Loss $0.54 a Share, vs. FactSet Est of $0.50 Loss  marketscreener.com

Earnings Flash (URGN) UroGen Pharma Posts Q4 Net Loss $0.54 a Share, vs. FactSet Est of $0.50 Loss - marketscreener.com

Click here to get full coverage on H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - Yahoo Finance

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy  Yahoo Finance

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - Yahoo Finance

Click here to get full coverage on UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target - Yahoo Finance

UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target  Yahoo Finance

UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target - Yahoo Finance

Click here to get full coverage on UroGen Pharma stock jumps after positive Phase 3 trial results - Investing.com

UroGen Pharma stock jumps after positive Phase 3 trial results  Investing.com

UroGen Pharma stock jumps after positive Phase 3 trial results - Investing.com

Click here to get full coverage on UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  GlobeNewswire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Click here to get full coverage on Earnings Preview: URGN to Report Financial Results Pre-market on November 06 - Moomoo

Earnings Preview: URGN to Report Financial Results Pre-market on November 06  Moomoo

Earnings Preview: URGN to Report Financial Results Pre-market on November 06 - Moomoo

Click here to get full coverage on 3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends  MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

Click here to get full coverage on UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - GlobeNewswire

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum  GlobeNewswire

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - GlobeNewswire

Click here to get full coverage on UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on UroGen Pharma Secures New $250 Million Term Loan - tipranks.com

UroGen Pharma Secures New $250 Million Term Loan  tipranks.com

UroGen Pharma Secures New $250 Million Term Loan - tipranks.com

Click here to get full coverage on UroGen’s revenue set to double by 2026 on bladder cancer drug rollout - S&P Global

UroGen’s revenue set to double by 2026 on bladder cancer drug rollout  S&P Global

UroGen’s revenue set to double by 2026 on bladder cancer drug rollout - S&P Global

Click here to get full coverage on Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - The Motley Fool

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally  The Motley Fool

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - The Motley Fool

Click here to get full coverage on UroGen (URGN) Reports Q3 Revenue Miss; Focuses on ZUSDURI's Grow - GuruFocus

UroGen (URGN) Reports Q3 Revenue Miss; Focuses on ZUSDURI's Grow  GuruFocus

UroGen (URGN) Reports Q3 Revenue Miss; Focuses on ZUSDURI's Grow - GuruFocus

Click here to get full coverage on Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - Yahoo Finance

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally  Yahoo Finance

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - Yahoo Finance

Click here to get full coverage on The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline - URGN - PR Newswire

The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline - URGN  PR Newswire

The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline - URGN - PR Newswire

Click here to get full coverage on UroGen Pharma at H.C. Wainwright Conference: Zosduri’s Market Impact - Investing.com

UroGen Pharma at H.C. Wainwright Conference: Zosduri’s Market Impact  Investing.com

URGN

Price Chart

Key Statistics

Technicals

About URGN

Latest News

URGN SEC Filings - Urogen Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities - Yahoo Finance

URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe - GuruFocus

Advanced Charts

Top Gainers

Top Losers